Stocks · News reference
Nasus Pharma Enrolls And Doses First Patient In Phase 1 Study Of NS003 Intranasal Formulation Of Ondansetron
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nasus Pharma Announces CFO Eyal Rubin To Depart September 18; Appoints Oren Elmaliach As Interim CFO
Nasus Pharma H1 EPS $(0.54) Misses $(0.20) Estimate
Nasus Pharma (AMEX:NSRX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.20) by 170 percent. This is a 217.65 percent decrease over losses of $(0.17) per share from the